De Bernardi di Valserra M, Feletti F, Bertè F, Nazzari M, Cenedese A, Cornelli U
Istituto di Farmacologia Medica II, Università degli Studi di Pavia, Italy.
Eur J Clin Pharmacol. 1988;34(2):211-2. doi: 10.1007/BF00614561.
The bioavailability of diclofenac (D) was assessed in 12 healthy volunteers treated orally with single doses of 100 mg (retard formulation) and subsequently retreated with the same dose of (D) plus sulglicotide (S) 200 mg. (D) blood levels were measured by GLC in samples collected after 1, 2, 4, 6, 8, 12, 24 h. No relevant difference was seen in (D) bioavailability after (S) administration; after 8 h plasma levels of (D) were slightly higher after (S) (p less than 0.05), but this difference can be considered incidental only. Thus, sulglicotide does not interfere with the bioavailability of diclofenac, and can be administered concurrently with the latter to prevent possible gastric injury by the antiinflammatory drug.
在12名健康志愿者中评估了双氯芬酸(D)的生物利用度,这些志愿者口服单剂量100mg(缓释制剂),随后再用相同剂量的(D)加200mg舒糖肽(S)进行治疗。在给药后1、2、4、6、8、12、24小时采集的样本中,通过气相色谱法测量(D)的血药浓度。给予(S)后,(D)的生物利用度未见相关差异;给予(S)后8小时,(D)的血浆水平略高(p小于0.05),但这种差异仅可视为偶然。因此,舒糖肽不干扰双氯芬酸的生物利用度,并且可以与后者同时给药,以预防抗炎药可能造成的胃损伤。